Wylie Hosmer, MD
Hematology & Oncology · Southington, CTNPI 1720136757
Payments from drug & device makers
What this record shows
This record is dominated by other: $2,030 of the $2,339 with a category attached, or 86.8%. Novartis accounts for 86.8% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $1,294, more than ten times the $36 reported in 2019.
Across 33 payments — averaging $70.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Medtronic$135
- Array Biopharma Inc$51
- Gilead$45
- Pfizer$36
- Bristol Myers Squibb$26
- plus $18 from 1 others
Across 30 payments — averaging $36,463 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$681K
- Amgen$329K
- Genentech, Inc.$37K
- Pfizer$30K
- Boehringer Ingelheim International GmbH$14K
- United Therapeutics Corporation$2K
- plus $500 from 1 others
What the payments were for
- Food & beverage$26211%
- Education$482%
- Other$2,03087%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $2,030 |
| Medtronic | 1 | $135 |
| Array Biopharma Inc | 3 | $51 |
| Gilead | 2 | $45 |
| Pfizer | 3 | $36 |
| Bristol Myers Squibb | 1 | $26 |
| Johnson & Johnson | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$135
How this compares
$2,339 in reported general payments places this provider in the 55th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 69 | $1,317,185 |
| TagrissoOsimertinib Mesylate | 40 | $665,892 |
| IbrancePalbociclib | 39 | $632,426 |
| BrukinsaZanubrutinib | 49 | $625,847 |
| InlytaAxitinib | 24 | $481,361 |
| IclusigPonatinib Hcl | 17 | $349,999 |
| LenvimaLenvatinib Mesylate | 12 | $295,133 |
| KisqaliRibociclib Succinate | 17 | $235,721 |
| VerzenioAbemaciclib | 13 | $201,286 |
| NinlaroIxazomib Citrate | 12 | $152,629 |
| VenclextaVenetoclax | 26 | $143,312 |
| XtandiEnzalutamide | 11 | $130,245 |
| EliquisApixaban | 154 | $117,178 |
| LonsurfTrifluridine/Tipiracil Hcl | 12 | $116,878 |
| XareltoRivaroxaban | 75 | $76,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $26 | $1,317,18569 claims |
| PfizerIbrance, Inlyta, Eliquis | $36 | $1,230,965217 claims |
| NovartisKisqali | $2,030 | $235,72117 claims |
| Johnson & JohnsonXarelto | $18 | $76,18175 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in Southington
- Peter ByeffSouthington$13K
- Amer ZeidanNew Haven$807K
- Biree AndemariamFarmington$646K
- Paul WeinsteinStamford$288K
- Walid ShaibNew Haven$217K
- Madhavi GorusuHartford$207K
- Dinesh KapurNorwich$201K
- Scott HuntingtonNew Haven$163K
- Nataliya UbohaNew Haven$124K
- Michael CecchiniNew Haven$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.